Neupro
Neupro is a transdermal patch formulation of rotigotine, a non-ergoline dopamine agonist. It is applied to the skin once daily and provides continuous delivery of the active drug over 24 hours. It helps stimulate dopamine receptors in the brain to improve motor function in Parkinson's disease and reduce sensory/motor symptoms in Restless Legs Syndrome.
Dosage by Body Weight
Dosage is highly individualized and must be titrated under medical supervision. The patch is applied once daily to clean, dry, intact skin of the abdomen, thigh, hip, flank, shoulder, or upper arm. The application site must be rotated daily, avoiding the same spot for at least 14 days. For Restless Legs Syndrome (RLS), therapy typically starts at 1 mg/24 hr. For Parkinson's disease, therapy typically starts at 2 mg/24 hr and may be titrated up weekly based on clinical response.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established. |
| 5-7 kg | Not recommended | N/A | Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established. |
| 8-10 kg | Not recommended | N/A | Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established. |
| 11-15 kg | Not recommended | N/A | Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established. |
| 16-20 kg | Not recommended | N/A | Neupro is not indicated or studied for pediatric populations. Safety and effectiveness have not been established. |
Formulation
Purpose
Treatment of the signs and symptoms of Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS).
Generic Name
RotigotineScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.